Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’

Abstract

Although less than 1% of patients with the antiphospholipid syndrome (APS) develop the catastrophic variant, its potentially lethal outcome emphasizes its importance in clinical medicine today. However, the rarity of this variant makes it extraordinarily difficult to study in any systematic way. In order to put together all of the published case reports as well as the new diagnosed cases from all over the world, an international registry of patients with catastrophic APS (CAPS Registry) was created in 2000 by the European Forum on Antiphospholipid Antibodies (see http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM). Currently, it documents the entire clinical, laboratory and therapeutic data of more than 300 patients whose data has been fully registered.

Keywords

anticardiolipin antibodies antiphospholipid antibodies antiphospholipid syndrome catastrophic antiphospholipid syndrome lupus anticoagulant

Get full access to this article

View all access options for this article.

References

Asherson RA The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-512.

Piette JC , Cervera R. , Levy R. , Nasonov EL , Triplett DA , Shoenfeld Y. The catastrophic antiphospholipid syndrome - Asherson’s syndrome . Ann Med Intern 2003; 154: 95-96.

Asherson RA , Cervera R. , Piette JC , et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore ) 1998; 77: 195-207.

Asherson RA , Cervera R. , Piette JC , et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine ( Baltimore) 2001; 80: 355-376.

Cervera R. , Piette JC , Font J. , et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.

Asherson RA , Cervera R. , de Groot PR , et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.

Cervera R. , Font J. , Gómez-Puerta JA , et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205-1209.

Cervera R. , Bucciarelli S. , Plasín MA , et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the ‘‘CAPS Registry’’ . J Autoimmun 2009; 32: 240-245.

Bucciarelli S. , Espinosa G. , Asherson RA , et al. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients . Ann Rheum Dis 2006 ; 65: 81-86.

10.

Asherson RA , Espinosa G. , Cervera R. , et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005; 64: 943-946.

11.

Espinosa G. , Bucciarelli S. , Cervera R. , et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-736.

12.

Bucciarelli S. , Espinosa G. , Cervera R. , et al. Mortality in catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients . Arthritis Rheum 2006; 54: 2568-2576.

13.

Erkan D. , Asherson RA , Espinosa G. , et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62: 530-533.

14.

Bayraktar UD , Erkan D. , Bucciarelli S. , Espinosa G. , Asherson RA , for the Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumato 2007; 34: 346-352.

15.

Asherson R. , Espinosa G. , Menahen S. , et al. Relapsing catastrophic antiphospholipid syndrome: Report of three cases. Semin Arthritis Rheum 2008; 37: 366-372.